Royalty Pharma Plc (RPRX)

$26.4

+0.18

(+0.69%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $26.27
    $26.66
    $26.40
    downward going graph

    0.48%

    Downside

    Day's Volatility :1.44%

    Upside

    0.96%

    downward going graph
  • $25.10
    $31.66
    $26.40
    downward going graph

    4.92%

    Downside

    52 Weeks Volatility :20.71%

    Upside

    16.6%

    downward going graph

Returns

PeriodRoyalty Pharma PlcSector (Health Care)Index (Russel 2000)
3 Months
-5.0%
-7.6%
0.0%
6 Months
-3.5%
-2.3%
0.0%
1 Year
-2.89%
10.1%
0.0%
3 Years
-37.39%
7.5%
-24.5%

Highlights

Market Capitalization
15.3B
Book Value
$15.40
Dividend Share
0.83
Dividend Yield
3.23%
Earnings Per Share (EPS)
2.54
PE Ratio
10.24
PEG Ratio
5.38
Wall Street Target Price
41.528
Profit Margin
50.53%
Operating Margin TTM
130.17%
Return On Assets TTM
5.69%
Return On Equity TTM
17.28%
Revenue TTM
2.3B
Revenue Per Share TTM
5.06
Quarterly Revenue Growth YOY
5.3%
Gross Profit TTM
1.3B
EBITDA
1.5B
Diluted Eps TTM
2.54
Quarterly Earnings Growth YOY
6.59
EPS Estimate Current Year
3.91
EPS Estimate Next Year
4.22
EPS Estimate Current Quarter
0.93
EPS Estimate Next Quarter
1.06

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Royalty Pharma Plc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 57.3%

Current $26.40
Target $41.53

Company Financials

FY18Y/Y Change
Revenue
1.8B
↑ 12.33%
Net Income
1.4B
↑ 13.86%
Net Profit Margin
76.76%
↑ 1.04%
FY19Y/Y Change
Revenue
1.8B
↑ 1.08%
Net Income
2.3B
↑ 70.46%
Net Profit Margin
129.45%
↑ 52.69%
FY20Y/Y Change
Revenue
2.1B
↑ 16.96%
Net Income
495.2M
↓ 78.91%
Net Profit Margin
23.34%
↓ 106.11%
FY21Y/Y Change
Revenue
2.3B
↑ 7.89%
Net Income
478.8M
↓ 3.32%
Net Profit Margin
20.91%
↓ 2.43%
FY22Y/Y Change
Revenue
2.2B
↓ 2.28%
Net Income
42.8M
↓ 91.05%
Net Profit Margin
1.91%
↓ 19.0%
FY23Y/Y Change
Revenue
2.4B
↑ 5.24%
Net Income
1.1B
↑ 2549.5%
Net Profit Margin
48.2%
↑ 46.29%
Q2 FY23Q/Q Change
Revenue
538.2M
↓ 21.31%
Net Income
227.6M
↓ 33.2%
Net Profit Margin
42.29%
↓ 7.53%
Q3 FY23Q/Q Change
Revenue
536.3M
↓ 0.35%
Net Income
72.1M
↓ 68.32%
Net Profit Margin
13.45%
↓ 28.84%
Q4 FY23Q/Q Change
Revenue
596.0M
↑ 11.13%
Net Income
494.3M
↑ 585.5%
Net Profit Margin
82.94%
↑ 69.49%
Q1 FY24Q/Q Change
Revenue
568.0M
↓ 4.7%
Net Income
4.8M
↓ 99.03%
Net Profit Margin
0.84%
↓ 82.1%
Q2 FY24Q/Q Change
Revenue
537.3M
↓ 5.41%
Net Income
102.0M
↑ 2034.87%
Net Profit Margin
18.99%
↑ 18.15%
Q3 FY24Q/Q Change
Revenue
564.7M
↑ 5.1%
Net Income
544.0M
↑ 433.3%
Net Profit Margin
96.33%
↑ 77.34%
FY18Y/Y Change
Total Assets
11.4B
-
Total Liabilities
6.8B
-
FY19Y/Y Change
Total Assets
12.4B
↑ 9.5%
Total Liabilities
6.3B
↓ 7.47%
FY20Y/Y Change
Total Assets
21.1B
↑ 69.46%
Total Liabilities
6.1B
↓ 2.92%
FY21Y/Y Change
Total Assets
17.5B
↓ 16.97%
Total Liabilities
7.3B
↑ 18.67%
FY22Y/Y Change
Total Assets
16.8B
↓ 4.01%
Total Liabilities
7.3B
↑ 0.29%
FY23Y/Y Change
Total Assets
16.4B
↓ 2.57%
Total Liabilities
6.3B
↓ 13.59%
Q2 FY23Q/Q Change
Total Assets
17.1B
↑ 0.28%
Total Liabilities
7.3B
↑ 0.77%
Q3 FY23Q/Q Change
Total Assets
15.9B
↓ 7.39%
Total Liabilities
6.3B
↓ 14.2%
Q4 FY23Q/Q Change
Total Assets
16.4B
↑ 3.32%
Total Liabilities
6.3B
↑ 0.43%
Q1 FY24Q/Q Change
Total Assets
16.1B
↓ 1.53%
Total Liabilities
6.3B
↓ 0.48%
Q2 FY24Q/Q Change
Total Assets
17.7B
↑ 9.46%
Total Liabilities
7.9B
↑ 26.13%
Q3 FY24Q/Q Change
Total Assets
18.0B
↑ 2.18%
Total Liabilities
7.8B
↓ 1.53%
FY18Y/Y Change
Operating Cash Flow
1.6B
↑ 14.1%
Investing Cash Flow
303.4M
↓ 119.11%
Financing Cash Flow
-1.4B
↑ 1018.91%
FY19Y/Y Change
Operating Cash Flow
1.7B
↑ 3.02%
Investing Cash Flow
-2.2B
↓ 809.77%
Financing Cash Flow
-1.2B
↓ 13.59%
FY20Y/Y Change
Operating Cash Flow
2.0B
↑ 22.04%
Investing Cash Flow
-2.8B
↑ 28.12%
Financing Cash Flow
1.5B
↓ 224.79%
FY21Y/Y Change
Operating Cash Flow
2.0B
↓ 0.84%
Investing Cash Flow
-1.9B
↓ 32.22%
Financing Cash Flow
385.1M
↓ 74.1%
FY22Y/Y Change
Operating Cash Flow
2.1B
↑ 6.27%
Investing Cash Flow
-1.0B
↓ 44.96%
Financing Cash Flow
-944.9M
↓ 345.35%
Q2 FY23Q/Q Change
Operating Cash Flow
607.8M
↓ 41.21%
Investing Cash Flow
-63.4M
↓ 88.64%
Financing Cash Flow
-347.0M
↑ 64.94%

Technicals Summary

Sell

Neutral

Buy

Royalty Pharma Plc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Royalty Pharma Plc
Royalty Pharma Plc
-5.51%
-3.5%
-2.89%
-37.39%
-41.08%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-23.25%
-25.21%
-6.95%
15.49%
111.91%
Biontech Se
Biontech Se
-8.46%
10.94%
5.13%
-68.25%
419.0%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-14.8%
66.28%
52.0%
33.04%
123.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.62%
2.09%
27.19%
148.61%
109.39%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Royalty Pharma Plc
Royalty Pharma Plc
10.16
10.24
5.38
3.91
0.17
0.06
0.03
15.4
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.73
18.73
1.13
44.87
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Royalty Pharma Plc
Royalty Pharma Plc
Buy
$15.1B
-41.08%
10.16
50.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.2B
111.91%
18.73
33.61%
Biontech Se
Biontech Se
Buy
$23.9B
419.0%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
123.73%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.3B
109.39%
32.84
-4.51%

Insights on Royalty Pharma Plc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 537.26M → 564.69M (in $), with an average increase of 4.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 4.77M → 543.98M (in $), with an average increase of 88.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 52.0% return, outperforming this stock by 54.9%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 37.5% return, outperforming this stock by 74.4%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    19.79%

  • Vanguard Group Inc

    8.43%

  • FMR Inc

    6.25%

  • BlackRock Inc

    5.16%

  • Baillie Gifford & Co Limited.

    3.61%

  • Viking Global Investors LP

    2.68%

Corporate Announcements

  • Royalty Pharma Plc Dividends March,2024

    In the quarter ending March,2024. Royalty Pharma Plc has declared dividend of $0.21

    Read More

Company Information

royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi

Organization
Royalty Pharma Plc
Employees
0
CEO
Mr. Pablo Gerardo Legorreta
Industry
Health Technology

FAQs